Generation Bio Co.
| NASDAQ: GBIO | Healthcare / Biotechnology / USA |
| 27.20 | -1.44 | -5.03% | Vol 690.63K | 1Y Perf 11.06% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 27.14 | ASK | 27.20 | ||
| Open | 28.94 | Previous Close | 28.64 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 42.25 | Analyst Rating | — — 0.00 | |
| Potential % | 55.33 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.53B | Earnings Rating | — | |
| Price Range Ratio 52W % | 26.34 | Earnings Date | 23rd Mar 2021 |
Today's Price Range 27.1029.07 | 52W Range 17.0055.72 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.42% | ||
| 1 Month | -22.95% | ||
| 3 Months | -2.61% | ||
| 6 Months | -3.37% | ||
| 1 Year | 11.06% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -95.06 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -47.89 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -25.25 | |||
Return on invested Capital Q | -8.74 | |||
Return on invested Capital Y | -95.06 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.20 | ||||
| 5.99 | ||||
| - | ||||
| - | ||||
| -28.70 | ||||
| -2.57 | ||||
| 5.99 | ||||
| 4.75 | ||||
| 1.40B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 23.40 | ||||
| 23.90 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.52 | -0.53 | -1.92 |
| Q03 2020 | -0.45 | -0.46 | -2.22 |
| Q02 2020 | -0.60 | -1.50 | -150.00 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.51 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 690.63K |
| Shares Outstanding | 56.43M |
| Trades Count | 5.70K |
| Dollar Volume | 18.59M |
| Avg. Volume | 695.96K |
| Avg. Weekly Volume | 460.46K |
| Avg. Monthly Volume | 692.05K |
| Avg. Quarterly Volume | 588.82K |
Generation Bio Co. (NASDAQ: GBIO) stock closed at 27.2 per share at the end of the most recent trading day (a -5.03% change compared to the prior day closing price) with a volume of 690.64K shares and market capitalization of 1.53B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 85 people. Generation Bio Co. CEO is Geoffrey McDonough.
The one-year performance of Generation Bio Co. stock is 11.06%, while year-to-date (YTD) performance is -4.06%. GBIO stock has a five-year performance of %. Its 52-week range is between 17 and 55.72, which gives GBIO stock a 52-week price range ratio of 26.34%
Generation Bio Co. currently has a PE ratio of -10.20, a price-to-book (PB) ratio of 5.99, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.89%, a ROC of -25.25% and a ROE of -95.06%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Generation Bio Co., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Generation Bio Co.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Generation Bio Co. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Generation Bio Co. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Generation Bio Co. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Generation Bio Co. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.11, ATR14 : 4.14, CCI20 : -19.18, Chaikin Money Flow : -0.04, MACD : 0.81, Money Flow Index : 56.55, ROC : -5.51, RSI : 51.45, STOCH (14,3) : 46.97, STOCH RSI : 0.34, UO : 48.58, Williams %R : -53.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Generation Bio Co. in the last 12-months were:
Generation Bio Co.
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
CEO: Geoffrey McDonough
Telephone: +1 617 655-7500
Address: 301 Binney Street, Cambridge 02142, MA, US
Number of employees: 85
